Evidence map›Paper›PMID 20129933›Full record

ArticleBrain : a journal of neurology2010

Novel forms of neurofascin 155 in the central nervous system: alterations in paranodal disruption models and multiple sclerosis.

Anthony D Pomicter, Seema M Shroff, Babette Fuss, Carmen Sato-Bigbee, Peter J Brophy, Matthew N Rasband, Manzoor A Bhat, Jeffrey L Dupree

Erratum issuedOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Brain : a journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. From PNS to CNS: characteristics of anti-neurofascin 186 neuropathy in 16 cases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Article
  6. Article
  7. mNeuron · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Anthony D PomicterDepartment of Anatomy and Neurobiology, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA.
Seema M Shroff
Babette Fuss
Carmen Sato-Bigbee
Peter J Brophy
Matthew N Rasband
Manzoor A Bhat
Jeffrey L Dupree
Virginia Commonwealth University · USBaylor College of Medicine · USUniversity of Edinburgh · GBUniversity of North Carolina at Chapel Hill · US

Funding

Molecular Organization &Function of Paranodal JunctionsR01GM063074 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BHAT, MANZOOR A. · 2001 to 2023
$5.8M
Determining the mechanisms that regulate neurofascin155 distribution in myelinR03NS066186 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI DUPREE, JEFFREY L. · 2009 to 2010
$149k
Medical Research Council G0301172NIGMS NIH HHS GM063074NIGMS NIH HHS R01 GM063074NINDS NIH HHS NS066186NINDS NIH HHS R03 NS066186
6 · The paper itself

Abstract

Stability of the myelin-axon unit is achieved, at least in part, by specialized paranodal junctions comprised of the neuronal heterocomplex of contactin and contactin-associated protein and the myelin protein neurofascin 155. In multiple sclerosis, normal distribution of these proteins is altered, resulting in the loss of the insulating myelin and consequently causing axonal dysfunction. Previously, this laboratory reported that mice lacking the myelin-enriched lipid sulphatide are characterized by a progressive deterioration of the paranodal structure. Here, it is shown that this deterioration is preceded by significant loss of neurofascin 155 clustering at the myelin paranode. Interestingly, prolonged electrophoretic separation revealed the existence of two neurofascin 155 bands, neurofascin 155 high and neurofascin 155 low, which are readily observed following N-linked deglycosylation. Neurofascin 155 high is observed at 7 days of age and reaches peak expression at one month of age, while neurofascin 155 low is first observed at 14 days of age and constantly increases until 5 months of age. Studies using conditional neurofascin knockout mice indicated that neurofascin 155 high and neurofascin 155 low are products of the neurofascin gene and are exclusively expressed by oligodendrocytes within the central nervous system. Neurofascin 155 high is a myelin paranodal protein while the distribution of neurofascin 155 low remains to be determined. While neurofascin 155 high levels are significantly reduced in the sulphatide null mice at 15 days, 30 days and 4 months of age, neurofascin 155 low levels remain unaltered. Although maintained at normal levels, neurofascin 155 low is incapable of preserving paranodal structure, thus indicating that neurofascin 155 high is required for paranodal stability. Additionally, comparisons between neurofascin 155 high and neurofascin 155 low in human samples revealed a significant alteration, specifically in multiple sclerosis plaques.

Indexed as

Disease Models, AnimalAdultAgedAged, 80 and overAnimalsCell Adhesion MoleculesCentral Nervous SystemFemaleHumansMaleMiceMice, KnockoutMiddle AgedMultiple SclerosisNerve Growth FactorsProtein IsoformsCell Adhesion MoleculesNerve Growth FactorsNfasc protein, mouseProtein Isoforms

Identifiers

PMID20129933
PMCPMC2822635
OpenAlexW2015265210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.